55
Participants
Start Date
June 30, 2010
Primary Completion Date
February 28, 2014
Study Completion Date
February 28, 2014
panobinostat
PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
bortezomib
dexamethasone
Montefiore Medical Center, The Bronx
Duke University Medical Center Dept. of DUMC (4), Durham
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst., Atlanta
Georgia Regents University MedCollege of GA Cancer Ctr 2, Augusta
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt UMC, Nashville
Medical College of Wisconsin, Milwaukee
Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc., Skokie
MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston
University of California at Los Angeles, Los Angeles
Stanford University Medical Center Division of Hematology, Stanford
Dana Farber Cancer Institute, Boston
Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2), Somerset
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY